Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children (CyNCh)
Cysteamine Bitartrate Delayed-Release for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Children (CyNCh)
Sponsor: National Cancer Institute (NCI)
This PHASE2/PHASE3 trial investigates Nonalcoholic Fatty Liver Disease (NAFLD) and is currently completed. National Cancer Institute (NCI) leads this study, which shows 10 recorded versions since 2012 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Oct 2022 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Sep 2021 — Oct 2022 [monthly]
Completed PHASE2_PHASE3
▶ Show 5 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE2_PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
-
Oct 2017 — Jun 2018 [monthly]
Completed PHASE2_PHASE3
-
Feb 2017 — Oct 2017 [monthly]
Completed PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2_PHASE3
First recorded
Jun 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- National Center for Advancing Translational Sciences (NCATS)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Raptor Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .